Receive Breaking News updates as they occur
By Kate Kelland LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed. The vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola -- the one circulating in West Africa -- and the first doses for a larger trial arrived in Liberia last week. Johnson & Johnson and Bavarian Nordic have a vaccine in early-stage clinical tests. The early-stage Phase I trial of GSK's vaccine was primarily designed to test safety, but Adrian Hill, who led the work at Oxford's Jenner Institute, said it was "encouraging" that the shot also prompted responses from the immune system.
ESKI MOSUL, Iraq (AP) — An unarmed Sunni Arab man walked along a road in a patch of northern Iraq newly liberated from Islamic State extremists, holding a white surrender flag — a signal to Kurdish fighters that he is not a militant. Cars drove by, a similar white banner flying from their windows.